Langer-backed biotech reboots with $38M, new name and new cancer drug tech

John Carroll

Four-year-old Blend Therapeutics, launched with the scientific backing of MIT's Robert Langer and colleagues, is jettisoning its one-time lead program and focusing on a new top and platform with a $ 38 million C round. And it's taking a new to help underscore the shift in focus.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS